4 documents

The latest follow-on from Human Genome Sciences Inc. (NASDAQ:HGSI) will increase its cash to around $1.1 billion, more than enough to get Benlysta belimumab to market for systemic lupus erythematosus. Indeed, if all goes well,...

Apoptos (San Diego, Calif.) raised about $14 million in the first of two tranches of a $28 million series A round led by existing investor Venrock. New investors OrbiMed Advisors and Advanced Technology Ventures joined...